These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21486448)

  • 21. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
    Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
    Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.
    Fang C; Zhuang Y; Wang L; Fan L; Wu YJ; Zhang R; Zou ZJ; Zhang LN; Yang S; Xu W; Li JY
    Cancer Sci; 2013 Aug; 104(8):996-1001. PubMed ID: 23659384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma.
    Piris MA; Mollejo M; Campo E; Menárguez J; Flores T; Isaacson PG
    Histopathology; 1998 Sep; 33(3):230-9. PubMed ID: 9777389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classification of small B-cell lymphoid neoplasms using a paraffin section immunohistochemical panel.
    Chen CC; Raikow RB; Sonmez-Alpan E; Swerdlow SH
    Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):1-11. PubMed ID: 10937042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
    Carulli G; Cannizzo E; Zucca A; Buda G; Orciuolo E; Marini A; Petrini M
    Leuk Res; 2008 Feb; 32(2):263-7. PubMed ID: 17692374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.
    Delgado J; Matutes E; Morilla AM; Morilla RM; Owusu-Ankomah KA; Rafiq-Mohammed F; del Giudice I; Catovsky D
    Am J Clin Pathol; 2003 Nov; 120(5):754-9. PubMed ID: 14608903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.
    Wang L; Abbasi F; Gaigalas AK; Vogt RF; Marti GE
    Cytometry B Clin Cytom; 2006 Nov; 70(6):410-5. PubMed ID: 16967494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases.
    Kroft SH; Dawson DB; McKenna RW
    Am J Clin Pathol; 2001 Mar; 115(3):385-95. PubMed ID: 11242795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
    Almasri NM; Duque RE; Iturraspe J; Everett E; Braylan RC
    Am J Hematol; 1992 Aug; 40(4):259-63. PubMed ID: 1380203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic utility of PD-1 in B cell lymphomas.
    Muenst S; Hoeller S; Willi N; Dirnhofera S; Tzankov A
    Dis Markers; 2010; 29(1):47-53. PubMed ID: 20826917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
    Clarke LE; Bayerl MG; Ehmann WC; Helm KF
    J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD5-expressing B-cell lymphomas/leukemias: relatively high frequency of CD5+ B-cell lymphomas with an overall poor prognosis in Nagasaki Japan.
    Kamihira S; Hirakata Y; Atogami S; Sohda H; Tsuruda K; Yamada Y; Tomonaga M
    Leuk Lymphoma; 1996 Jun; 22(1-2):137-42. PubMed ID: 8724541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K; Terui Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.
    Rossmann ED; Lundin J; Lenkei R; Mellstedt H; Osterborg A
    Hematol J; 2001; 2(5):300-6. PubMed ID: 11920265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
    Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L
    Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of non-Hodgkin's lymphomas with rituximab in Slovene patients.
    Jezersek Novaković B; Benigar A
    Med Oncol; 2010 Jun; 27(2):167-76. PubMed ID: 19263255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
    Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
    Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study.
    Borowitz MJ; Shuster J; Carroll AJ; Nash M; Look AT; Camitta B; Mahoney D; Lauer SJ; Pullen DJ
    Blood; 1997 Jun; 89(11):3960-6. PubMed ID: 9166833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.